Fig. 4: In vivo activity and protective efficacy of 8-9D mRNA. | Nature Communications

Fig. 4: In vivo activity and protective efficacy of 8-9D mRNA.

From: A lung-selective delivery of mRNA encoding broadly neutralizing antibody against SARS-CoV-2 infection

Fig. 4: In vivo activity and protective efficacy of 8-9D mRNA.The alternative text for this image may have been generated using AI.

a Schematic for distribution and kinetics analysis of 8-9D mRNA after injection. C57BL/6 mice were i.v. injected with 5 μg of 8-9D mRNA with Lung-LNPs or Liver-LNPs as the delivery system. The animals (n = 5) were euthanized at 24 h post injection. b–e The sera (b), BALF (c), livers (d), and lungs (e) were collected for 8-9D detection by ELISA. 8-9D kinetics levels in BALF (f) and lungs (g) were further measured for the samples (n = 3) collected on day 2, 4, 8, 15, and 21 post injection. IL-6, TNF-α and IL-1β levels in sera at 1 day, 2 days, 4 days, and 8 days post injection of Lung-LNPs@mRNA8-9D (h–j). Data are presented as mean ± SD and representative of two independent experiments with similar results. P values were determined by one-way ANOVA with Tukey’s multiple comparison post-hoc test. Source data are provided as a Source data file.

Back to article page